Subscribe to BCA Journal Know More

January 2019

FROM PUBLISHED ACCOUNTS

By Himanshu V. Kishnadwala
Chartered Accountant
Reading Time 18 mins

Segment Reporting as per IndAS 108

Compilers’ Note:

As compared to AS 17 ‘Segment Reporting’, Ind AS 108 ‘Operating Segments’ has changed the manner in which segment identification is done and has also mandated several additional disclosures. These disclosures are required in line to be what internally the company reports to its ‘Chief Operating Decision Maker (“CODM”). Given below is a compilation of the extracts of disclosures given in the financial statements for the year ended 31st March 2018 from few companies in different industries.

 

  1. REDDY’S LABORATORIES LTD

From Significant Accounting Policies:

Segment Reporting:

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. Refer 2.24 for segment information presented.

From Notes to Financial Statements

Segment Reporting:

The Chief Operating Decision Maker (“CODM”) evaluates the Company’s performance and allocates resources based on an analysis of various performance indicators by operating segments. The CODM reviews revenue and gross profit as the performance indicator for all of the operating segments, and does not review the total assets and liabilities of an operating segment. The Chief Executive Officer is the CODM of the Company.

The Company’s reportable operating segments are as follows:

  • Global Generics;
  • Pharmaceutical Services and Active Ingredients (“PSAI”); and
  • Proprietary Products.

Global Generics: This segment consists of the Company’s business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed either under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company’s biologics business.

Pharmaceutical Services and Active Ingredients: This segment consists of the Company’s business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also known as “API” or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediates become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes the Company’s contract research services business and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.

Proprietary Products: This segment consists of the Company’s business that focuses on the research, development, and manufacture of differentiated formulations and new chemical entities (“NCEs”). These novel products fall within the dermatology and neurology therapeutic areas and are marketed and sold through Promius ® Pharma, LLC.

Others: This includes the operations of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with established pharmaceutical and biotechnology companies in early-stage collaborations, bringing drug candidates from hit generation to pre-clinical development.

The measurement of each segment’s revenues, expenses and assets is consistent with the accounting policies that are used in preparation of the Company’s consolidated financial statements.

Segment Information:

(1) Revenue for the year ended 31st March 2018 does not include inter-segment revenues from PSAI segment to Global Generics segment which amounts to Rs. 5,492 (as compared to Rs. 6,181 for the year ended 31st March 2017).

(2) Post implementation of Goods and Services Tax (“GST”) with effect from 1st July 2017, sales is disclosed net of GST. Sales for the year ended 31st March 2017 included excise duty of Rs. 939 which is now subsumed in the GST. Sales for the year ended 31 March 2018 includes excise duty of Rs. 173 up to 30th June 2017. Accordingly, sales for the year ended 31st March 2018 are not comparable with those of the previous year presented.

Analysis of revenue by geography:

The following table shows the distribution of the Company’s revenues (excluding other operating income) based on the location of the customers:

REPORTABLE SEGMENTS FOR THE YEAR ENDED 3rd MARCH 2018
  GLOBAL GENERICS PSAI PROPRIETARY PRODUCTS OTHERS TOTAL
Revenue from operations(1)(2) 114,282 22,438 4,250 1,840 142,810
Gross profit 67,190 4,477 3,799 869 76,335
Less: Selling and other unallocable expense/ (income), net         62,831
Profit before tax         13,504
Tax expense         4,380
Profit after tax         9,124
Add: Share of profit of equity accounted investees, net of tax         344
Profit for the year         9,468

 

REPORTABLE SEGMENTS FOR THE YEAR ENDED 3rd MARCH 2017
  GLOBAL GENERICS PSAI PROPRIETARY PRODUCTS OTHERS TOTAL
Revenue from operations(1) (2) 115,736 21,651 2,783 1,791 141,961
Gross profit 71,079 4,497 1,951 853 78,380
Less: Selling and other unallocable expense/(income), net         62,843
Profit before tax         15,537
Tax expense         2,965
Profit after tax         12,572
Add: Share of profit of equity accounted investees, net of tax         349
Profit for the year         12,921

 

COUNTRY FOR THE YEAR ENDED

31st MARCH 2018

FOR THE YEAR ENDED

31st MARCH 2017

India 25,209 24,927
United States 68,124 69,816
Russia 12,610 11,547
Others 36,085 34,519
Total 142,028 140,809

 

Analysis of revenue within the Global Generics segment:

An analysis of revenue (excluding other operating income) by therapeutic areas in the Company’s Global Generics segment is given below:

 

PARTICULARS FOR THE YEAR ENDED

31st MARCH 2018

FOR THE YEAR ENDED

31st MARCH 2017

Gastrointestinal 19,153 21,190
Oncology 16,999 17,054
Cardiovascular 16,501 15,553
Pain Management 12,898 14,323
Central Nervous System 12,509 12,749
Anti-Infective 6,557 7,189
Others 29,397 27,351
Total 114,014 115,409

 

Analysis of revenue within the PSAI segment:

An analysis of revenues (excluding other operating income) by therapeutic areas in the Company’s PSAI segment is given below:

 

PARTICULARS FOR THE YEAR ENDED

31st MARCH 2018

FOR THE YEAR ENDED

31st MARCH 2017

Cardiovascular 6,191 5,078
Pain Management 3,228 3,290
Central Nervous System 2,331 2,758
Anti-Infective 1,968 1,859
Dermatology 1,606 1,606
Oncology 1,650 1,534
Others 5,018 5,152
Total 21,992 21,277

 

Analysis of assets by geography:

The following table shows the distribution of the Company’s non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets:

 

COUNTRY AS AT

31st MARCH 2018

AS AT

31st MARCH 2017

India 61,997 61,031
Switzerland 32,202 31,457
United States 8,483 8,233
Germany 2,968 2,560
Others 5,930 5,001
Total 111,580 108,282

 

The following table shows the distribution of the Company’s property, plant and equipment including capital work in progress and intangible assets acquired during the year (other than goodwill arising on business combination) by country, based on the location of assets:

 

COUNTRY FOR THE YEAR ENDED

31st MARCH 2018

FOR THE YEAR ENDED

31st MARCH 2017

India 8,093 10,545
Switzerland 1,100 26,639
United States 779 2,657
Others 1,830 728
Total 11,802 40,569

 

Analysis of depreciation and amortisation, for arriving gross profit by reportable segments:

 

PARTICULARS FOR THE YEAR ENDED

31 MARCH 2018

FOR THE YEAR ENDED

31 MARCH 2017

Global Generics 3,549 3,334
PSAI 2,887 2,647
Proprietary Products
Others 94 89
Total 6,530 6,070

 

Information about major customers

Revenues from two of the customers of the Company’s Global Generics segment were Rs.13,486 and Rs.10,755 representing approximately 9% and 8% of the Company’s total revenues, respectively for the year ended 3rd March 2018.

Revenues from one of the customers of the Company’s Global Generics segment were Rs. 22,760 representing approximately 16% of the Company’s total revenues, for the year ended 31st March 2017.

INFOSYS LTD

From Notes to Financial Statements

 

Segment Reporting:

Ind AS 108 establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. The Group’s operations predominantly relate to providing end-to-end business solutions to enable clients to enhance business performance. Based on the ‘management approach’ as defined in Ind AS 108, the Chief Operating Decision Maker (CODM) evaluates the Group’s performance and allocates resources based on an analysis of various performance indicators by business segments and geographic segments. Accordingly, information has been presented both along business segments and geographic segments. The accounting principles used in the preparation of the financial statements are consistently applied to record revenue and expenditure in individual segments, and are as set out in the significant accounting policies.

Business segments of the Group are primarily enterprises in Financial Services (FS), enterprises in Manufacturing (MFG), enterprises in Retail, Consumer packaged goods and Logistics (RCL), enterprises in the Energy & utilities, Communication and Services (ECS), enterprises in Hi-tech (Hi-tech), enterprises in Life Sciences, Healthcare and Insurance (HILIFE) and all other segments. The FS reportable segments has been aggregated to include the Financial Services operating segment and the Finacle operating segment because of the similarity of the economic characteristics. All other segments represent the operating segments of businesses in India, Japan, China and IPS. Geographic segmentation is based on business sourced from that geographic region and delivered from both onsite and offshore locations. North America comprises the United States of America, Canada and Mexico, Europe includes continental Europe (both the east and the west), Ireland and the United Kingdom, and the Rest of the World comprises all other places except those mentioned above and India.

Revenue and identifiable operating expenses in relation to segments are categorized based on items that are individually identifiable to that segment. Revenue for ‘all other segments’ represents revenue generated by IPS and revenue generated from customers located in India, Japan and China. Allocated expenses of segments include expenses incurred for rendering services from the Company’s offshore software development centres and onsite expenses, which are categorised in relation to the associated turnover of the segment. Certain expenses such as depreciation, which form a significant component of total expenses, are not specifically allocable to specific segments as the underlying assets are used interchangeably. The Management believes that it is not practical to provide segment disclosures relating to those costs and expenses, and accordingly these expenses are separately disclosed as ‘unallocated’ and adjusted against the total income of the Group.

Assets and liabilities used in the Group’s business are not identified to any of the reportable segments, as these are used interchangeably between segments. The management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous.

Geographical information on revenue and business segment revenue information is collated based on individual customers invoiced or in relation to which the revenue is otherwise recognised.

Business Segment

For the years ended 31st March 2018 and March 31st 2017.

 

(In Rs. Crore)
Particulars FS MFG ECS RCL HILIFE Hi-Tech All other

segments

Total
Revenue from operations 18,638 7,699 16,757 11,104 9,271 5,047 2,006 70,522
  18,555 7,507 15,430 11,225 8,437 5,122 2,208 68,484
Identifiable operating expenses 9,476 4,135 8,411 5,339 4,596 2,679 1,162 35,798
  9,271 3,922 7,430 5,378 4,178 2,659 1,406 34,244
Allocated expenses 3,955 1,745 3,796 2,516 2,100 1,144 455 15,711
  4,075 1,737 3,569 2,598 1,951 1,186 510 15,626
Segmental operating income 5,207 1,819 4,550 3,249 2,575 1,224 389 19,013
  5,209 1,848 4,431 3,249 2,308 1,277 292 18,614
Unallocable expenses               1,865
                1,713
Other income, net (Refer to Notes 2.17 and 2.25)               3,193
                3,080
Share in net profit / (loss) of associate, including impairment               (71)
                (30)
Profit before tax               20,270
                19,951
Tax expense               4,241
                5,598
Profit for the year               16,029
                14,353
Depreciation and amortisation expense               1,863
                1,703
Non-cash expenses other than depreciation and amortisation               191
                28

 

Geographic segments

For the years ended 31st March 2018 and March 2017:

 

  In Rs. crore
  Particulars North America Europe India Rest of the World Total
  Revenue from operations 42,575 16,738 2,231 8,978 70,522
    42,408 15,392 2,180 8,504 68,484
  Identifiable operating expenses 22,105 8,535 906 4,252 35,798
    21,618 7,694 1,002 3,930 34,244
  Allocated expenses 9,624 3,778 426 1,883 15,711
    9,799 3,548 442 1,837 15,626
  Segmental operating income 10,846 4,425 899 2,843 19,013
    10,991 4,150 736 2,737 18,614
  Unallocable expenses         1,865
            1,713
  Other income, net

(Refer to Notes 2.17 and 2.25)

        3,193
            3,080
  Share in net profit / (loss) of

associate, including impairment

        (71)
            (30)
  Profit before tax         20,270
            19,951
  Tax expense         4,241
In Rs. crore  
Particulars North America Europe India Rest of the World Total  
          5,598  
Profit for the year         16,029  
          14,353  
Depreciation and amortisation expense         1,863  
          1,703  
Non-cash expenses other than depreciation and amortisation         191  
          28  

 

Significant clients

No client individually accounted for more than 10% of the revenues in the years ended 31st March 2018 and 31st March 2017.

 

RELIANCE INDUSTRIES LTD

From Notes to Financial Statements

 

Segment Information

The Group’s operating segments are established on the basis of those components of the Group that are evaluated regularly by the Executive Committee (the ‘Chief Operating Decision Maker’ as defined in Ind AS 108 – ‘Operating Segments’), in deciding how to allocate resources and in assessing performance. These have been identified taking into account nature of products and services, the different risks and returns and the internal business reporting systems.

The Group has five principal operating and reporting segments; viz; Refining, Petrochemicals, Oil and Gas, Organised Retail and Digital Services.

The accounting policies adopted for segment reporting are in line with the accounting policy of the Company with following additional policies for segment reporting.

  1. Revenue and Expenses have been identified to a segment on the basis of relationship to operating activities of the segment. Revenue and Expenses which relate to enterprise as a whole and are not allocable to a segment on reasonable basis have been disclosed as “Unallocable”.
  2. Segment Assets and Segment Liabilities represent Assets and Liabilities in respective segments. Investments, tax related assets and other assets and liabilities that cannot be allocated to a segment on a reasonable basis have been disclosed as “Unallocable”.

 

(i)  Primary Segment Information

Not reproduced…..

(ii)  Inter segment pricing are at Arm’s length basis.

(iii) As per Indian Accounting Standard 108 – Operating Segments, the Company has reported segment information on consolidated basis including business conducted through its subsidiaries.

(iv) The reportable segments are further described below:

–    The Refining segment includes production and marketing operations of the petroleum products.

–    The Petrochemicals segment includes production and marketing operations of petrochemicals products namely. High density Polythylene, Low density Polyethylene, Linear Low density Polyethylene, Polypropylene, Polyvinyl Chloride, Polyester Yarn, Polyester Fibres, Purified Terephthalic Acid, Paraxylene, Ethylene Glycol, Olefins, Aromatics, Linear Alkyl Benzene, Butadienc, Acrylonitrile, Poly Butadiene Rubber, Styrene Butadiene Rubber, Caustic Soda and Polyethylene Terephthalate.

–    The Oil and Gas segment includes exploration, development and production of crude oil and natural gas.

–    The organised Retail segment includes organise retail business in India.

–    The Digital Services segment includes range of digital services in India.

–    The business, which were not reportable segments during the year, have been grouped under the ‘Others’ segment.   This mainly comprises of:

  • Media
  • SEZ Development
  • Textile

 

(v)   Secondary Segment Information:

 

Rs. in crore
    2017-18 2016-17
1 Segment Revenue – External Turnover
  Within India 2,09,093 1,52,197
  Outside India 2,21,638 1,77,983
  Total 4,30,731 3,30,180
2 Non – Current Assets 
  Within India 6,09,272 5,38,852
  Outside India 23,290 26,674
  Total 6,32,562 5,65,526

 

ITC LTD

From Significant Accounting Policies

Operating Segments

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker (CODM). The CODM, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Corporate Management Committee.

Segments are organised based on business which have similar economic characteristics as well as exhibit similarities in nature of products and services offered, the nature of production processes, the type and class of customer and distribution methods.

Segment revenue arising from third party customers is reported on the same basis as revenue in the financial statements. Inter-segment revenue is reported on the basis of transactions which are primarily market led. Segment results represent profits before finance charges, unallocated corporate expenses and taxes.

“Unallocated Corporate Expenses” include revenue and expenses that relate to initiatives / costs attributable to the enterprise as a whole and are not attributable to segments.

 

   
(Rs. in Crores)
    2018   2017  
External Inter Segment Total External Inter Segment Total
1. Segment Revenue-Gross
  FMCG-Cigarettes 24848.09 24848.09 35877.66 35877.66
FMCG-Others 11339.31 18.07 11357.38 10523.53 13.90 10537.46
FMCG-Total 36187.40 18.07 36205.47 46401.22 13.90 46415.12
Hotels 1480.02 14.65 1494.67 1400.35 14.04 1414.39
Agri Business 4474.22 3680.82 8155.04 5314.13 3070.73 8384.86
Paperboards, Paper and

Packaging

3695.41 1554.23 5249.64 3732.63 1630.23 5362.86
Others 1525.46 76.97 1602.43 1439.62 74.06 1513.68
Segment Total 47362.51 5344.74 52707.25 58287.95 4802.96 63090.91
Eliminators     (5344.74)     (4802.96)
Gross Revenue from sale of products and services     47362.51     58287.95
2. Segment Results
  FMCG-Cigarettes     14128.12     13203.70
  FMCG-Others     170.46     26.15
  FMCG-Total     14298.58     13229.85
  Hotels     145.00     117.12
  Agri Business     841.49     926.32

 

(Rs. in Crores)
    2018   2017  
External Inter Segment Total External Inter Segment Total
  Paperboards, Paper and

Packaging

    1042.16     965.84
  Others     126.81     102.71
  Segment Total     16454.04     15341.84
  Eliminators     (93.60)     41.46
  Consolidated Total     16360.44     15383.30
  Unallocated corporate expenses net of unallocated income     1020.29     1007.60
  Profit before interest etc., and taxation     15340.15     14375.70
  Finance Costs     89.91     24.30
  Interest earned on loans and deposits, income from current and non-current investments, profit and

loss on sale of investments etc.-Net

    1738.39     1668.95
  Share of net profit of

associates & joint ventures

    7.58     5.97
  Exceptional Items [refer note 28(i)]     412.90    
  Profit before tax     17409.11     16026.32
  Tax expense     5916.43     5549.09
  Profit for the year     11492.68     10477.23
3. Other Information 2018 2017
        Segment

Assets

Segment

Liabilities

Segment

Assets

Segment

Liabilities

  FMCG-Cigarettes     8508.42 4756.35 8573.92 2561.31
  FMCG-Others     7760.11 1909.42 7257.61 1411.58
  FMCG-Total     16268.53 6665.77 15831.53 3972.89
  Hotels (Refer Note 3B)     6564.68 619.34 5849.59 446.94
  Agri Business     3693.37 807.75 3255.76 723.60
  Paperboards, Paper and

Packaging

    6730.78 786.73 6313.82 623.85
  Others     900.81 229.54 771.74 209.52
  Segment Total     34158.17 9109.13 32022.44 5976.80
  Unallocated Corporate

Assets/Liabilities

    30130.69 2335.15 23920.83 3258.80
  Total     64288.86 11444.28 55943.27 9235.50

 

*Segment Liabilities of FMCG – cigarettes is before considering `233.02 Crore (2017 – Rs. 629.83 crore) in respect of disputed taxes, the recovery of which has been stayed or where States’ appeals are pending before Courts. These have been included under ‘Unallocated Corporate Liabilities’. Also Refer Note 28(i).

 

(Rs. in Crores)
  2018 2017
  Capital expenditure Depreciation and amortisation Capital expenditure Depreciation and amortisation
FMCG – Cigarettes 96.23 295.15 262.35 305.15
FMCG – Others 835.85 301.97 1157.41 246.08
FMCG – Totals 932.08 597.12 1419.76 551.23
Hotels 918.64 174.98 472.19 172.31
Agri business 92.90 68.04 160.63 50.42
Paperboards, Paper and Packaging 910.01 274.60 560.63 254.14
Others 16.25 25.68 10.46 28.53
Segment Total 2869.88 1140.42 2623.37 1056.63
Unallocated 327.65 95.86 553.76 96.16
Total 3197.53 1236.28 3177.43 1152.79

 

  Non Cash Expenditure other than depreciation Non Cash Expenditure other than depreciation
FMCG – Cigarettes 2.44 3.42
FMCG – Others 48.55 40.14
FMCG – Totals 50.99 43.56
Hotels 6.89 11.30
Agri Business 2.33 0.52
Paperboards, Paper and

Packaging

44.32 22.97
Others 4.89 5.67
Segment Total 109.42 84.02

 

GEOGRAPHICAL INFORMATION

 

    2018 2017
1. Revenue from External Customers    
   – Within India 41175.15 51796.82
   – Outside India 6187.36 6491.13
  Total 47362.51 58287.95
       
2. Non-Current Assets    
   – Within India 23341.21 21816.13
   – Outside India 1245.68 1009.85
  Total 24586.89 22825.98

 

NOTES:

1)    The Group’s corporate strategy aims at creating multiple drivers of growth anchored on its core competencies. The Group is currently focused on four business groups: FMCG, Hotels, Paperboards, Paper and Packaging and Agri Business. The Group’s organisation structure and governance process are designed to support effective management of multiple businesses while retaining focus on each one of them.

The Operating Segments have been reported in a manner consistent with the internal reporting provided to the corporate Management Committee, which is the Chief Operating Decision Maker.

2)    The business groups comprise the following

FMCG :           Cigarettes         –     Cigarettes, Cigars etc.

Others   –     Branded  packaged  foods  business  (Staples, Snacks    and meals; Dairy and Beverages; Confections),   Apparels,     education     and stationery product, personal care product, safety matches and agarbattis.

Hotels                                              Hoteliering

Paperboards, Paper and Packaging       –         Paperboards, paper including speciality paper

 

 

and packaging including flexibles.

Agri Business       –      Agri commodities such as soya, spices, coffee and leaf tobacco.

Others                  –    Information Technology service etc.

 

 

3)    The Group companies have been included in segment classification as follows:

FMCG  :                 Cigarettes             –     Surya Nepal Private Limited

Others :                –     Surya Nepal Private Limited and North East Nutrients

Private Limited.

 

Hotels                    –     Srinivasa  Resorts  Limited,  Fortune  Park  Hotels Limited, Bay Island Hotels Limited and Welcome Hotels Lanka (Private) Limited.

 

Agri Business          –     Technico   Agri   Science   Limited,   Technico   Pty Limited and its subsidiaries Technico Technology Inc., alongwith its jointly controlled operations with Shamrock  Seed  Potato  Farm  Limited,  Technico Asia Holdings Pty Limited and Technico Hoticulture (Kunming) Co. Limited.

 

Others                   –      ITC  Infotech  India  Limited  and  its  subsidiaries ITC  Infotech  Limited,  ITC  Infotech  (USA).  Inc and Indivate Inc. Russell Credit Limited and its Subsidiaries Greenacre Holdings Limited, Wimco Limited, Pravan Poplar Limited, Prag Agro Farm Limited, ITC investments and Holding Limited and its Subsidiary MRR Trading and Investment Company Limited, Land Based India Limited and Gold Flake Corporation Limited.

 

4)    The geographical Information considered for disclosure are:

–     Sales within India

–     Sales outside India

 

5)    Segment result of “FMCG: Other” are after considering significant business development, brand Building and

Gestation cost of the Branded Package Foods business and Personal Care products and business

 

6)    As stocks options are granted under ITC ESOS to align the interest of employees with those shareholders and also to attract and retain talent for the group as a whole, the option value of ITC ESOS do not form part of segment performance reviewed by corporate management committee.

 

7)    The Group is not reliant on revenue from transactions from any single external customer and does not receive 10%

or more of its revenue from its transactions with any single external customer.

You May Also Like